Manufacturing | Process Control
Monday, May 2, 2022
Manufacturing quality and cost are critical for enabling rapid growth in GCT. Panelists will explore a variety of critical questions in this space. For example, are there historic parallels that can be drawn between GCT manufacturing and other groundbreaking technologies? How do key manufacturing concerns in GCT differ from those for more conventional pharmaceutical? What are the long-term opportunities for non-viral vectors? Will manufacturing capacity be a limiting factor in GCT growth over the next 5 to 10 years?
- Moderator:
-
- John Bishai, PhD
-
- Managing Director, Global Investment Banking, BofA Securities
- Panelists:
-
- Christopher Murphy
-
- Vice President Viral Vector Services, Thermo Fisher
- Michael Paglia
-
- COO, ElevateBio BaseCamp, ElevateBio
- Rahul Singhvi, ScD
-
- CEO, National Resilience, Inc.
- Ran Zheng
-
- CEO, Landmark Bio